I-MAB-SPONSORED ADR (IMAB) Fundamental Analysis & Valuation

NASDAQ:IMAB • US44975P1030

Current stock price

4.63 USD
-0.01 (-0.22%)
At close:
4.72 USD
+0.09 (+1.94%)
After Hours:

This IMAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IMAB Profitability Analysis

1.1 Basic Checks

  • In the past year IMAB has reported negative net income.
  • IMAB had negative earnings in 4 of the past 5 years.
  • In the past 5 years IMAB reported 4 times negative operating cash flow.
IMAB Yearly Net Income VS EBIT VS OCF VS FCFIMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

  • The Return On Assets of IMAB (-18.22%) is better than 77.61% of its industry peers.
  • IMAB has a Return On Equity of -19.14%. This is amongst the best in the industry. IMAB outperforms 84.70% of its industry peers.
Industry RankSector Rank
ROA -18.22%
ROE -19.14%
ROIC N/A
ROA(3y)-42.75%
ROA(5y)-32.49%
ROE(3y)-60.9%
ROE(5y)-45.09%
ROIC(3y)N/A
ROIC(5y)N/A
IMAB Yearly ROA, ROE, ROICIMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

  • IMAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMAB Yearly Profit, Operating, Gross MarginsIMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. IMAB Health Analysis

2.1 Basic Checks

  • IMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IMAB has been increased compared to 1 year ago.
  • The number of shares outstanding for IMAB has been increased compared to 5 years ago.
  • There is no outstanding debt for IMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMAB Yearly Shares OutstandingIMAB Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
IMAB Yearly Total Debt VS Total AssetsIMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • IMAB has an Altman-Z score of 23.66. This indicates that IMAB is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 23.66, IMAB belongs to the top of the industry, outperforming 91.60% of the companies in the same industry.
  • IMAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.66
ROIC/WACCN/A
WACC8.67%
IMAB Yearly LT Debt VS Equity VS FCFIMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

  • A Current Ratio of 22.86 indicates that IMAB has no problem at all paying its short term obligations.
  • The Current ratio of IMAB (22.86) is better than 95.90% of its industry peers.
  • A Quick Ratio of 22.86 indicates that IMAB has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 22.86, IMAB belongs to the top of the industry, outperforming 95.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 22.86
Quick Ratio 22.86
IMAB Yearly Current Assets VS Current LiabilitesIMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. IMAB Growth Analysis

3.1 Past

  • IMAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.81%, which is quite impressive.
  • IMAB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)89.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.65%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 9.68% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.8%
EPS Next 2Y29.17%
EPS Next 3Y14.99%
EPS Next 5Y9.68%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMAB Yearly Revenue VS EstimatesIMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2028 2029 2030 2031 2032 0 500M 1B 1.5B
IMAB Yearly EPS VS EstimatesIMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. IMAB Valuation Analysis

4.1 Price/Earnings Ratio

  • IMAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMAB Price Earnings VS Forward Price EarningsIMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMAB Per share dataIMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IMAB's earnings are expected to grow with 14.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.17%
EPS Next 3Y14.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMAB Dividend Analysis

5.1 Amount

  • IMAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

IMAB Fundamentals: All Metrics, Ratios and Statistics

I-MAB-SPONSORED ADR

NASDAQ:IMAB (10/29/2025, 8:00:02 PM)

After market: 4.72 +0.09 (+1.94%)

4.63

-0.01 (-0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-20
Earnings (Next)04-01
Inst OwnersN/A
Inst Owner Change10.79%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap533.68M
Revenue(TTM)N/A
Net Income(TTM)-37.71M
Analysts85
Price Target8.5 (83.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.51%
Min EPS beat(2)-61.76%
Max EPS beat(2)54.75%
EPS beat(4)1
Avg EPS beat(4)-12.75%
Min EPS beat(4)-61.76%
Max EPS beat(4)54.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.05%
PT rev (3m)38.89%
EPS NQ rev (1m)-12.5%
EPS NQ rev (3m)-12.5%
EPS NY rev (1m)39.39%
EPS NY rev (3m)61.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.71
P/tB 2.71
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS1.71
TBVpS1.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.22%
ROE -19.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.75%
ROA(5y)-32.49%
ROE(3y)-60.9%
ROE(5y)-45.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.86
Quick Ratio 22.86
Altman-Z 23.66
F-ScoreN/A
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)76.01%
Cap/Depr(5y)97.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.65%
EPS Next Y89.8%
EPS Next 2Y29.17%
EPS Next 3Y14.99%
EPS Next 5Y9.68%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-161.06%
EBIT Next 3Y34.96%
EBIT Next 5Y74.68%
FCF growth 1Y56.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.04%
OCF growth 3YN/A
OCF growth 5YN/A

I-MAB-SPONSORED ADR / IMAB Fundamental Analysis FAQ

What is the fundamental rating for IMAB stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMAB.


What is the valuation status for IMAB stock?

ChartMill assigns a valuation rating of 0 / 10 to I-MAB-SPONSORED ADR (IMAB). This can be considered as Overvalued.


What is the profitability of IMAB stock?

I-MAB-SPONSORED ADR (IMAB) has a profitability rating of 1 / 10.


What is the financial health of I-MAB-SPONSORED ADR (IMAB) stock?

The financial health rating of I-MAB-SPONSORED ADR (IMAB) is 8 / 10.